- Clone:
- REAL146
- Type of antibody:
- Releasable antibodies, Primary antibodies, Recombinant antibodies
- Applications:
- FC, MICS, IF, IHC Glossary
- Select a conjugate:
- Select a size:
Related products for CD54 (ICAM-1) Antibody, anti-human, REAlease®
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Cells were incubated with an excess of purified unconjugated CD54 (ICAM-1) (REAL146) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.
To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.
Fluorescence microscopy image of CD54 (ICAM-1) knockout cells. Wild type (WT, left) and knockout cells (KO, right) were stained with CD54 (ICAM-1)-PE (REAL146, red) and counterstained with DRAQ5 (blue) as DNA stain.
Overlay histogram showing flow cytometric analysis of human CD54 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD54-PE, clone (REAL146). Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
Flow cytometric comparison of different clones for CD54 (ICAM-1). Human peripheral blood mononuclear cells (PBMCs) were stained with CD54 (ICAM-1)antibodies and with a suitable counterstaining. As a control, CD54 (ICAM-1) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
Comparison of staining pattern on non-fixed and fixed cells using CD54 (ICAM-1) (REAL146). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Clone REAL146 is an antibody fragment derived from the full CD54 (ICAM-1) antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.
Clone REAL146 recognizes human CD54, a 85–110 kDa type I transmembrane glycoprotein, which also known as intercellular adhesion molecule 1 (ICAM-1). CD54 is continuously present in low concentrations in the membranes of monocytes/macrophages, lymphocytes, activated endothelial cells, granulocytes, and dendritic cells. Its expression is regulated by inflammatory cytokines and can be induced by interleukin-1 and tumor necrosis factor. CD54 is a ligand for LFA-1, a receptor found on leukocytes. When activated, leukocytes bind to endothelial cells via CD54/LFA-1 and then transmigrate into tissues. CD54 has been shown to interact with CD11a, EZR, and CD18. More recently, CD54 has been characterized as a site for the cellular entry of human rhinovirus.
The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.
ICAM-1, BB2, P3.58
Technical specifications
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
- Simmons, D. et al. (1988) ICAM, an adhesion ligand of LFA-1, is homologous to the neural cell adhesion molecule NCAM. Nature 331 (6157): 624-627
- Greve, J. M. et al. (1989) The major human rhinovirus receptor is ICAM-1. Cell 56 (5): 839-847
- Shimaoka, M. et al. (2003) Structures of the α L I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell 112 (1): 99-111
You have previously chosen International as your location.
What do you want to do?